Skip to main content

Nonmelanoma Skin Cancers: Current and Emerging Checkpoint Inhibitors for Treating Advanced Basal Cell and Squamous Cell Carcinomas- GASCO


A CME/CNE/ABIM-MOC/MIPS Activity

TO REGISTER:
Click here to complete your registration.

DATES AND TIMES
Thursday, December 9, 2021
5:30 - 6:30 PM ET (4:30 - 5:30 PM CT / 3:30 - 4:30 PM MT / 2:30 - 3:30 PM PT)

Hosted by: Georgia Society of Clinical Oncology

If you will be watching the webinar in a group setting, please note all group participants will need to register individually in order to complete the post-test and evaluation to receive credit.

AGENDA
Welcome and Introduction
Evidence-based Diagnosis and Staging of Advanced Nonmelanoma Skin Cancers
Current and Emerging Therapies for Treating Advanced BCC and CSCC
Q&A Session and Activity Roundup

PROGRAM OVERVIEW
The incidence of nonmelanoma skin cancers (NMSC), including cutaneous squamous cell carcinomas (CSCC) and basal cell carcinomas (BCC), is increasing globally. Although these cancers are treatable with surgery or radiotherapy, locally advanced or metastatic forms of these carcinomas are life-threatening, difficult to treat, are not amenable to those standard options, and historically, have had few treatment options. Greater knowledge of the role of the immune system in the development of cancer, and of the role of programmed death-1 (PD-1) in evading immune clearance, has led to the study of PD-1 and PD-L1 inhibitors in the management of advanced and metastatic NMSCs. This research has led to the approval of a checkpoint inhibitor as the first treatment specifically for advanced CSCC and the continued development of checkpoint inhibitors for treating advanced BCC. Oncologists need to be aware of what constitutes a thorough diagnostic evaluation and accurate staging of patients to develop more effective individualized, evidence-based management plans. In addition, oncologists need to understand current evidence regarding the use of immunotherapies such as checkpoint inhibitors.

This program, Nonmelanoma Skin Cancers: Current and Emerging Checkpoint Inhibitors for Treating Advanced Basal Cell and Squamous Cell Carcinomas, will provide oncologists with current guideline-based diagnostic, staging, and treatment strategies for patients with advanced BCC and CSCC as well as how newly approved agents in development fit into treatment strategies.

STEERING COMMITTEE
  ROMAN GROISBERG, MD
  Assistant Professor, Medical Oncology
  Department of Melanoma and Sarcoma
  Rutgers Cancer Institute of New Jersey
  New Brunswick, NJ

  MAX LENOWITZ, CRNP
  Jefferson Medical Oncology
  Philadelphia, PA



  MELISSA WILSON, MD, PhD
  Medical Oncology Fellowship Program Director/Melanoma Program Director
  St. Luke’s Cancer Center – St. Luke’s University Health Network
  Easton, PA

TARGET AUDIENCE
The intended audience for this educational initiative is oncologists, oncology nurses, and other clinicians who are responsible for the diagnosis and management of patients with advanced NMSC (Non-Melanoma Skin Cancer).

EDUCATIONAL OBJECTIVES
At the conclusion of this education, participants should be able to:
  • Make timely diagnoses of patients with BCC or CSCC using current evidence-based criteria
  • Accurately stage and risk stratify patients with BCC or CSCC to establish optimal follow-up regimens
  • Make evidence-based treatment selections for patients with advanced BCC or CSCC
  • Assess the safety and efficacy of emerging therapies for advanced BCC or CSCC

PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION STATEMENT
The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions regarding CME credit or the evaluation, please email contact@potomacme.org.

NURSING ACCREDITATION AND DESIGNATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Rockpointe Corporation. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nurses (ANCC)
Amedco LLC designates this activity for a maximum of 1 ANCC contact hour.

ABIM MOC RECOGNITION STATEMENT
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS CREDIT DESIGNATION STATEMENT
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).

DISCLOSURE INFORMATION
The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

Disclosures will be made known to the participants prior to the start of the activity.

FDA DISCLOSURE
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME/CE CREDIT AND MOC POINTS
There is no fee for this activity. To receive credit, participants must register, view the live CME/MOC activity in its entirety, and then complete the post-test, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is one hour. To receive a certificate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times. For ABIM MOC points, your information will be shared with the ABIM through PCME’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

Jointly provided by the Potomac Center for Medical Education and Rockpointe


Nursing accreditation provided by Amedco


This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

PCME Privacy Policy